BRPI0516576A - vetores quiméricos - Google Patents

vetores quiméricos

Info

Publication number
BRPI0516576A
BRPI0516576A BRPI0516576-8A BRPI0516576A BRPI0516576A BR PI0516576 A BRPI0516576 A BR PI0516576A BR PI0516576 A BRPI0516576 A BR PI0516576A BR PI0516576 A BRPI0516576 A BR PI0516576A
Authority
BR
Brazil
Prior art keywords
vectors
chimeric vectors
relates
expressing
chimeric
Prior art date
Application number
BRPI0516576-8A
Other languages
English (en)
Inventor
Jiansheng Yao
Sheena May Loosmore
Jean-Christophe Francis Audonnet
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of BRPI0516576A publication Critical patent/BRPI0516576A/pt
Publication of BRPI0516576B1 publication Critical patent/BRPI0516576B1/pt
Publication of BRPI0516576B8 publication Critical patent/BRPI0516576B8/pt
Publication of BRPI0516576C8 publication Critical patent/BRPI0516576C8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VETORES QUIMéRICOS. A presente invenção refere-se a vetores quiméricos. Mais especificamente, a invenção refere-se a vetores de poxvírus e vírus recombinantes que são capazes de expressar um replicon de RNA alfaviral que expressa uma seqüência heteróloga de interesse.
BRPI0516576 2004-10-05 2005-10-04 Vetores quiméricos BRPI0516576C8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/958,267 US7998733B2 (en) 2004-10-05 2004-10-05 Chimeric vectors
US10/958,267 2004-10-05
PCT/US2005/035785 WO2006041897A2 (en) 2004-10-05 2005-10-04 Chimeric vectors

Publications (4)

Publication Number Publication Date
BRPI0516576A true BRPI0516576A (pt) 2008-09-16
BRPI0516576B1 BRPI0516576B1 (pt) 2019-09-24
BRPI0516576B8 BRPI0516576B8 (pt) 2021-05-25
BRPI0516576C8 BRPI0516576C8 (pt) 2022-06-14

Family

ID=36126051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516576 BRPI0516576C8 (pt) 2004-10-05 2005-10-04 Vetores quiméricos

Country Status (6)

Country Link
US (1) US7998733B2 (pt)
EP (1) EP1809337B1 (pt)
BR (1) BRPI0516576C8 (pt)
CA (1) CA2583147C (pt)
MX (1) MX2007004168A (pt)
WO (1) WO2006041897A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065476A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur A mammalian cell-based screening assay to identify inhibitors of alphaviruses
LT2734230T (lt) * 2011-07-20 2019-03-25 Merial Limited Rekombinantinė kačių leikemijos viruso vakcina, turinti optimizuotą kačių leukemijos viruso apvalkalo geną
NZ719934A (en) * 2013-11-28 2022-10-28 Bavarian Nordic As Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
DK3407910T3 (da) 2016-01-29 2022-07-18 Bavarian Nordic As Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus
KR20220129567A (ko) * 2019-12-31 2022-09-23 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
KR20220128367A (ko) * 2019-12-31 2022-09-20 엘릭서젠 쎄라퓨틱스, 인크. Zscan4 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
CN112143754B (zh) * 2020-09-30 2021-05-18 扬州大学 猪盖塔病毒感染性克隆及其建构方法及应用
WO2023097265A1 (en) * 2021-11-23 2023-06-01 Wisconsin Alumni Research Foundation Modified gene vaccines against avian coronaviruses and methods of using the same
US11873507B2 (en) 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
GB2624391A (en) * 2022-11-15 2024-05-22 Univ Cape Town Recombinant LSDV vectored bovine coronavirus antigen constructs

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001293222B2 (en) * 2000-08-29 2007-09-20 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles
DE60233061D1 (de) * 2001-09-06 2009-09-03 Alphavax Inc Alphavirus replikon-vektorsysteme
AU2003278695A1 (en) * 2002-05-28 2004-02-02 Maxygen, Inc. Nucleic acid vectors
ES2222095B1 (es) * 2003-07-02 2005-11-16 Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Virus adn recombinantes que comprenden un adn complementario de un replicon de un virus arn y sus aplicaciones.

Also Published As

Publication number Publication date
MX2007004168A (es) 2007-09-11
EP1809337A4 (en) 2008-02-13
EP1809337A2 (en) 2007-07-25
CA2583147A1 (en) 2006-04-20
WO2006041897A2 (en) 2006-04-20
BRPI0516576B1 (pt) 2019-09-24
CA2583147C (en) 2013-06-25
EP1809337B1 (en) 2017-08-23
BRPI0516576C8 (pt) 2022-06-14
BRPI0516576B8 (pt) 2021-05-25
US7998733B2 (en) 2011-08-16
US20060073594A1 (en) 2006-04-06
WO2006041897A3 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
BRPI0516576A (pt) vetores quiméricos
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
CY1115413T1 (el) Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
WO2014074648A3 (en) Riboregulator compositions and methods of use
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
CY1114509T1 (el) Αναστολεις της ns5a toy hcv
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
CY1118567T1 (el) Αναστολεις του ιου της ηπατιτιδας c
WO2006133911A3 (en) Hepatitis c virus nucleic acid vaccine
CL2011002426A1 (es) Compuestos derivados de benzo-diazol pirrolidina sustituidos, inhibidores de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica; y su uso para el tratamiento de una infeccion por vhc.
DK1954811T3 (da) Inducerbare ekspressionssystemer
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
SG177025A1 (en) Hepatitis b virus specific antibody and uses thereof
RS51324B (sr) Vakcine protiv nipah virusa
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
HRP20050705B1 (hr) Ekspresijski vektor koji sadrži promotor mcmv ie2
EA201491361A1 (ru) Ингибиторы вируса гепатита c
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
NO20090194L (no) Rekombinant viral vaksine
NZ609564A (en) Inhibitors of hepatitis c virus
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
EA201390806A1 (ru) Конструкция пептидного каркаса
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERIAL, INC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2542, DE 24/09/2019. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 24/09/2019, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)